Table 3 Summary of treatment-emergent adverse events in the etanercept and placebo groups
| Â | Double blind (week 8) | Open label (week 16) | Escape arm | |||
|---|---|---|---|---|---|---|
Finding | Etanercept 50 mg(n  = 42) | Placebo(n  = 48) | Etanercept 50 mg/etanercept 50 mg(n  = 31) | Placebo/etanercept 50 mg(n  = 33) | Etanercept 50 mg/etanercept 50 mg(n  = 6) | Placebo/etanercept 50 mg(n  = 11) |
Any adverse event | 34 (81.0) | 26 (54.2) | 12 (38.7) | 17 (51.5) | 6 (100.0) | 9 (81.8) |
Serious adverse event | 1 (2.4) | 2 (4.2) | 0 | 1 (3.0) | 0 | 0 |
Adverse event leading to discontinuation | 4 (9.5) | 0 | 0 | 2 (6.1) | 1 (16.7) | 0 |
Infections | 11 (26.2) | 10 (20.8) | 6 (19.4) | 8 (24.2) | 2 (33.3) | 4 (36.4) |
Serious infections | 0 | 0 | 0 | 0 | 0 | 0 |